<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">7756098</PMID>
        <DateCompleted>
            <Year>1995</Year>
            <Month>06</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0306-5251</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>39</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1995</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of clinical pharmacology</Title>
                <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.</ArticleTitle>
            <Pagination>
                <MedlinePgn>45-50</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>1. The haemodynamic effects of calcium antagonists could depend at least in part on the activity of vasoactive prostanoids. 2. We set out to study the effect of the cyclo-oxygenase inhibitor ibuprofen, 400 mg three times daily for 3 days, by a randomised cross-over study vs placebo in 12 mild to moderate essential hypertensive patients who had been treated for 1 month with amlodipine. 3. Blood pressure, heart rate and vascular resistances in the upper limb (Doppler ultrasound) were measured. Plasma renin activity and urinary aldosterone, as well as indices of renal function, were evaluated. Urinary 2,3-dinor-6-keto-PGF1 alpha and 2,3-dinor-TXB2, as well as 6-keto-PGF1 alpha and TXB2, were measured as indices of systemic and renal PGI2 and TXA2 synthesis. 4. Amlodipine normalised blood pressure and reduced upper limb vascular resistances; it did not affect urinary prostanoid excretion. Short-term combined administration of ibuprofen resulted in, by comparison with placebo, inhibition of systemic PGI2 (-80.5 ng 24 h-1, 95% CI -99.2, -61.4; P &lt; 0.001) and TXA2 (-216.1 ng 24 h-1, 95% CI -276.5, -155.8; P &lt; 0.001), together with an increase in systolic (+7.8 mm Hg, 95% CI +3.1, +12.3; P &lt; 0.01) and diastolic (+3.9 mm Hg, 95% CI +1.2, +6.6; P &lt; 0.01) blood pressure; it had no significant effect on regional vascular resistances (+4.7 mm Hg ml-1 s, 95% CI -5.6, +15.0). Effects of ibuprofen on renal prostanoid synthesis were less marked, and there was no change in indices of renal function or hydro-electrolytic balance.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Minuz</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto di Clinica Medica, Universit√† di Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pancera</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ribul</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Priante</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Degan</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campedelli</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arosio</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lechi</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>7503323</NlmUniqueID>
            <ISSNLinking>0306-5251</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016861">Cyclooxygenase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1J444QC288</RegistryNumber>
                <NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4964P6T9RB</RegistryNumber>
                <NameOfSubstance UI="D000450">Aldosterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>57576-52-0</RegistryNumber>
                <NameOfSubstance UI="D013928">Thromboxane A2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>58962-34-8</RegistryNumber>
                <NameOfSubstance UI="D015121">6-Ketoprostaglandin F1 alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AYI8EX34EU</RegistryNumber>
                <NameOfSubstance UI="D003404">Creatinine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DCR9Z582X0</RegistryNumber>
                <NameOfSubstance UI="D011464">Epoprostenol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.23.15</RegistryNumber>
                <NameOfSubstance UI="D012083">Renin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WK2XYI10QM</RegistryNumber>
                <NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D015121" MajorTopicYN="N">6-Ketoprostaglandin F1 alpha</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000450" MajorTopicYN="N">Aldosterone</DescriptorName>
                <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016861" MajorTopicYN="N">Cyclooxygenase Inhibitors</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011464" MajorTopicYN="N">Epoprostenol</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007052" MajorTopicYN="N">Ibuprofen</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012083" MajorTopicYN="N">Renin</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013928" MajorTopicYN="N">Thromboxane A2</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014655" MajorTopicYN="N">Vascular Resistance</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1995</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1995</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1995</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7756098</ArticleId>
            <ArticleId IdType="pmc">PMC1364980</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2125.1995.tb04408.x</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Prostaglandins. 1975 Oct;10(4):649-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1105697</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cardiovasc Pharmacol. 1992;19 Suppl 2:S22-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1377300</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Fed Proc. 1979 Jan;38(1):72-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">215464</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 1979 Jul;8(1):7-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">552299</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hypertension. 1981 Mar-Apr;3(2):168-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6260645</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Clin Pharmacol. 1982;22(3):197-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7049707</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Med. 1984 Jul 13;77(1A):51-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6431807</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Clin Pharmacol. 1985;29(4):413-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3912185</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1986 May 3;1(8488):997-1001</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2871333</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 1986 Jul;22(1):21-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2943308</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Med. 1986 Aug 25;81(2B):23-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3092663</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Med. 1986 Aug 25;81(2B):43-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3092665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Nephrol. 1986;6 Suppl 1:95-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3548365</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 1987 Nov;107(5):628-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2889416</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Med Sci. 1988 Apr;295(4):280-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3129942</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797-800</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3059352</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Prostaglandin Thromboxane Leukot Res. 1989;19:211-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2526471</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 1990 Mar;29(3):311-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2178660</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cardiovasc Drugs Ther. 1989 Dec;3(6):835-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2487545</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 1990 Oct;30(4):519-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2291866</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:963-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2076408</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Med. 1991 May 17;90(5A):42S-47S</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1903902</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Kidney Int Suppl. 1992 May;36:S43-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1614067</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Kidney Int Suppl. 1992 May;36:S49-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1614068</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prostaglandins. 1976 Aug;12(2):175-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">959582</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>